What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies

View Full Paper

Ask AI

Bookmark

The overall prevalence of monoclonal gammopathy was found to be 12.6% in 30,000 screened individuals, indicating significant concerns in high-risk groups.
Prevalence rates differ notably among racial groups, with Black individuals showing a higher incidence of monoclonal gammopathy, influencing screening guidelines.
Screening utilized advanced mass spectrometry and principal component analysis to identify risk factors, refining the assessment approach for monoclonal gammopathy.
This research underscores the need for tailored screening guidelines and awareness, addressing racial disparities and genetic predispositions in monoclonal gammopathy.

No takes yet. Share an insight, caveat, or question.

Prospective analysis reveals 12.6% prevalence of monoclonal gammopathy, indicating disparities in high-risk populations.

Allam et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark